- Home
- FMN vs ONCY Comparison
FMN vs ONCY Comparison
Compare FMN & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMN
- ONCY
- Stock Information
- Founded
- FMN 2002
- ONCY 1998
- Country
- FMN United States
- ONCY Canada
- Employees
- FMN N/A
- ONCY N/A
- Industry
- FMN Investment Managers
- ONCY Pharmaceuticals and Biotechnology
- Sector
- FMN Finance
- ONCY Health Care
- Exchange
- FMN Nasdaq
- ONCY Nasdaq
- Market Cap
- FMN 83.3M
- ONCY 89.7M
- IPO Year
- FMN N/A
- ONCY 1999
- Fundamental
- Price
- FMN $11.03
- ONCY $1.27
- Analyst Decision
- FMN
- ONCY Strong Buy
- Analyst Count
- FMN 0
- ONCY 5
- Target Price
- FMN N/A
- ONCY $5.00
- AVG Volume (30 Days)
- FMN 22.8K
- ONCY 1.2M
- Earning Date
- FMN 01-01-0001
- ONCY 11-11-2025
- Dividend Yield
- FMN 3.86%
- ONCY N/A
- EPS Growth
- FMN N/A
- ONCY N/A
- EPS
- FMN N/A
- ONCY N/A
- Revenue
- FMN N/A
- ONCY N/A
- Revenue This Year
- FMN N/A
- ONCY N/A
- Revenue Next Year
- FMN N/A
- ONCY N/A
- P/E Ratio
- FMN N/A
- ONCY N/A
- Revenue Growth
- FMN N/A
- ONCY N/A
- 52 Week Low
- FMN $9.09
- ONCY $0.33
- 52 Week High
- FMN $11.31
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- FMN 75.23
- ONCY 53.72
- Support Level
- FMN $10.93
- ONCY N/A
- Resistance Level
- FMN $11.07
- ONCY $1.44
- Average True Range (ATR)
- FMN 0.07
- ONCY 0.10
- MACD
- FMN 0.04
- ONCY -0.03
- Stochastic Oscillator
- FMN 91.80
- ONCY 88.19
About FMN Federated Hermes Premier Municipal Income Fund
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.